Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Labetalol vs Nifedipine for Postpartum Hypertension
NCT05309460Phase 4Recruiting
- Sponsor
- Methodist Health System
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of labetalol and nifedipine GITS in hypertension (HTN) and preeclampsia, sponsored by Methodist Health System. Primary endpoint: Hospital Readmission at 6 months. Started Jun 2022; status: recruiting.
02
Drugs
labetalolnifedipine GITS
03
Conditions
hypertension (HTN)preeclampsia
Beyond the preview
Go deeper on NCT05309460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309460.